Sustainability Commitment
Our commitment reflects our focus on improving health and safety through a people-centric culture, ethical leadership, and climate stewardship.
Purpose-Driven and Future-Focused
Our mission to improve patient health and safety guides everything we do—and shapes our commitment to sustainability. This deep sense of responsibility is reflected in how we operate as a business, with a focus on People-Centric Culture, Ethical Leadership, and Climate Stewardship.
Our SBTi-validated emissions reduction targets and EcoVadis Commitment badge reflect continued progress, and as part of our journey, have detailed action plans to continuously improve our rating.
Sustainability Starts with Our Core Principles
People-Centric Culture
We foster a culture of respect, inclusion, and opportunity to enable employee well-being, professional growth, and a culture of belonging.
- Dedicated DEI program and leadership
- Risk inventory assessments
- Volunteer and flexible time off
- Wellness benefits, annual programming, and challenges
- Employee Resource Groups and clubs
- Feedback and upward mobility
- Charity match programs
- Talent acquisition and retention
- Mentorship programs
- Training and continuous education opportunities
- And more!
Ethical Leadership
We uphold integrity, transparency, and accountability in all aspects of our business, ensuring responsible decision-making, data privacy, and compliance with global standards.
- Advanced Data Security and Privacy Programs
- Compliance with labor laws within each operating region
- Quarterly Board Reporting on Sustainability Program
- Transparent and accessible leadership through Town Halls
Climate Stewardship
We are focused on minimizing our environmental footprint through science-based climate action, responsible resource management, and continuous improvement in sustainability practices.
- Remote workforce commitment
- Employee Education & Green Team
- EcoVadis Commitment Badge
- Approved near- and long-term science-based emissions reduction targets with the Science Based Targets initiative (SBTi)
- Annual energy and carbon reporting
Our near-term and long-term emissions reduction targets have been independently validated by SBTi Services in accordance with the SBTi Near-Term and Net-Zero Criteria.
Driving Progress Through Collaboration
Our Sustainability Program is guided by a dedicated Steering Committee made up of executive and senior leaders from across our global operations. This cross-functional group is responsible for driving progress across all pillars of our sustainability strategy. The committee ensures accountability, approves new initiatives, and proactively plans for evolving regional requirements and standards to maintain meaningful, forward-looking impact.
News & Insights
June 22, 2026
A Risk-Based Road Map for Implementing AI
Discover a risk-based approach to implementing AI in life sciences, ensuring compliance, transparency, and governance throughout the entire lifecycle.
June 15, 2026
Five Metrics That Predict CRO Success (and How to Measure Them)
Discover five key metrics to evaluate CRO success, ensuring timely clinical trials and data integrity while minimizing costs. Learn how to measure them effectively.
June 18, 2026
ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...
ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.
May 27, 2026
ProPharma Appoints Adrian Pencak as Chief Commercial Officer
ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
June 17, 2026
Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...
Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...
June 10, 2026
Accelerating Commercial Readiness for a Novel Cell Therapy Program
As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...
June 2, 2026
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
June 17, 2026
Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...
Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...